March 08, 2023
In a new study published in Aging Cell, researchers have shown that two promising anti-aging agents, the antibiotic rapamycin and the anti-diabetic drug metformin, reverse aging in a population of intestinal stem cells [1]. The aging intestine Older people are more prone to gastrointestinal problems [2]. Moreover, aging is a major risk factor for various...
August 25, 2022
Scientists have found that rapamycin and metformin work hand in hand in diabetes-prone mice, boosting each other's effectiveness and blocking side effects [1]. The combination hypothesis Rapamycin and metformin are probably the two most promising anti-aging drugs known. Both have been in use for various indications for decades and have decent safety profiles. However, there...
July 11, 2022
This episode of Lifespan News features Ryan O'Shea discussing a recent study showing that metformin blunts the impact of exercise on performance. Script Metformin is a commonly prescribed diabetes drug, but it is also popular among biohackers and life extensionists who take it for what they believe to be its longevity benefits. While this use...
July 07, 2022
A study published in Frontiers in Neurology has detailed how three well-known longevity-associated compounds affect vascular cognitive impairment (VCI) in a rat model. A rat model of a common human disease In bilateral common carotid artery occlusion (BCCAO), the arteries of rats are sutured to reduce blood flow. This mimics arterial occlusion in human beings...
June 30, 2022
A study published in Obesity suggests that metformin may decrease the gains in cardiorespiratory performance brought on by exercise. The world's most common diabetes drug Metabolic syndrome, which is represented by the four connected symptoms of obesity, excessive fats in the bloodstream (dyslipidemia), high blood pressure (hypertension), and excessive blood sugar (hyperglycemia), all of which...
May 05, 2022
Richard A. Miller is a Professor of Pathology at the University of Michigan and the Director of Michigan's Paul F. Glenn Center for Biology of Aging Research. He is also a driving force behind the ITP, the Interventions Testing Program, created in the early 2000s to study the effect of various drugs on lifespan in...
